JOURNAL 1802
Organic Communications
Year: 2020 Issue: 3 July-September
p.89 - 102
Viewed 2084 times.
-
Ceyda Köse
-
Esra Uysal
-
Büşra Yazıcı
-
Serap İpek Dingiş-Birgül
-
Zeynep Tuğay
-
Hamdullah Yanık
-
Ece Tavukcuoglu
-
Sevgi Gülyüz
-
Atilla Akdemir
-
Güneş Esendağlı
-
Özgür Yılmaz
-
Onur Alptürk
GRAPHICAL ABSTRACT
ABSTRACT
Tumor cells benefit from some certain signals, which are referred to as “immune checkpoints”, to escape immune-mediated destruction. With that in mind, it is believed that the blockade of these points, such as programmed cell death Ligand-1 (PD-L1) and programmed cell death 1 (PD-1), can restore an adaptative immune response against tumoral cells. In this study, we have designed and synthesized some novel peptidomimetics with a 2-aminobenzathiazole scaffold, which targets the PD-1/PDL-1 pathway. In the viability assay, it was found that these compounds decreased the proliferation of peripheral blood mononuclear cells in the concentration of 10 uM. Overall, our results indicate that these novel compounds are potential checkpoint inhibitors for cancer immunotherapy.
KEYWORDS
- Immunotherapy
- PD-L1
- PD-1
- peptidomimetics
- 2-aminobenzothiazole
